T

he fight over who deserves key patents on the CRISPR-Cas9 genome-editing technology will have slightly less celebrity wattage than one side hoped: The three judges hearing the dispute at the US Patent and Trademark Office denied a request by the University of California to subpoena Harvard biologist George Church and UC student Shuailiang Lin, who formerly worked at the Broad Institute, which was awarded the fundamental CRISPR patent in 2014.

“UC has not explained why there would be a sufficient basis for a motion for additional testimony or for subpoena,” the judges ruled in an order published late Wednesday night.

UC wanted to depose Lin because he has made claims that seemed to weaken the case that Broad bioengineer Feng Zhang, in whose lab Lin worked from late 2011 to early 2012, deserved the key CRISPR patent. Zhang, Lin said in a 2015 email asking UC Berkeley biochemist Jennifer Doudna for a job, failed to make CRISPR work during that time. The Broad group succeeded, Lin alleged, only after Zhang and his colleagues read a seminal 2012 paper by Doudna and her team in which they constructed a CRISPR system that succeeded in cutting DNA in test tubes, the first step toward precise genome-editing.

advertisement

As for Church, UC argued that he could testify to two points it considers pivotal to its case. One is that Church (and perhaps Zhang) was inspired by Doudna’s paper, making the CRISPR breakthroughs they independently reported in 2013 (editing genomes in human and mouse cells) an obvious extension of her work not deserving of the patent awarded to the Broad based on Zhang’s breakthrough.

The second point would have involved whether that achievement could have been made by any POSITA, as patent lawyers say — a “person of ordinary skill in the art” of genetics. UC might have hoped that Church would call his work, and perhaps Zhang’s, just straightforward extensions of Doudna’s achievement and, by implication, not deserving of the patent.

The patent judges didn’t buy it.

“The standard for granting requests” for additional testimony, with or without a subpoena, “is high and requires specific bases for expecting that the discovery will be productive,” the judges wrote. “UC fails to explain why testimony from either Dr. Lin or Dr. Church regarding the timing of actual work done by Broad scientists would be productive.”

That suggests that the patent decision will turn on something other than the timing of discoveries — or at least that timing isn’t currently a focus. “Priority is not yet at issue,” the judges added. 

While the patent proceeding sometimes feels as if it has been going on since Crick and Watson discovered the structure of DNA, it’s just getting started. The judges haven’t even ruled on what the proper counts — the claims on which their decision will turn — will be.

Leave a Comment

Please enter your name.
Please enter a comment.

  • The essence of any structural biologist research work is to solve structures of proteins that cut or modify DNA, RNA and proteins in presence of other factors. Unfortunately, their work don’t match the drug discovery process. I wonder how many ever had the insight and creativity as that of geniuses who solved DNA’s structure.
    Without Feng’s insight, the case would have stayed as another dna cutting protein in the long list of already studied ones.

  • Say someone makes the world’s first car. Just a basic, slow car – nothing too exciting. Then, not much later, someones else comes along and suddenly makes a formula 1 race car with lots of features and new capabilities.

    Who is in this example the rightful inventor of the car?

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.